logo
Twitter
Discord
Email
logo
Acadia Healthcare Company, Inc.

Acadia Healthcare Company, Inc.

NASDAQ•ACHC
CEO: Mr. Christopher Howal Hunter
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1994-03-04
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Contact Information
6100 Tower Circle, Suite 1000, Franklin, TN, 37067, United States
615-861-6000
www.acadiahealthcare.com
Market Cap
$1.68B
P/E (TTM)
11.8
30.3
Dividend Yield
--
52W High
$47.08
52W Low
$17.13
52W Range
3%
3.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$851.57M+4.41%
4-Quarter Trend

EPS

$0.40-45.95%
4-Quarter Trend

FCF

$73.21M-370.05%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Nine Month Revenue Growth Nine month revenue reached $2.491B, marking 4.7% growth compared to prior year period.
Operating Cash Flow Surge Cash provided by operations totaled $218.2M for nine months, significantly up from $13.0M last year.
Total Assets Increase Total assets grew to $6.413B as of September 30, 2025, up from $5.957B at year-end 2024.
Facility Bed Expansion Added 908 beds in nine months through existing facility expansions and new wholly-owned/joint venture openings.

Risk Factors

Net Income Profit Decline Net income attributable to stockholders fell to $74.7M for nine months, down from $223.0M previously.
Investigation Cost Impact Government investigation costs drove transaction costs to $138.4M for nine months, impacting period results.
Ongoing Legal Exposure Multiple securities and derivative lawsuits remain pending; ultimate liability estimation is currently not possible.
Labor Market Pressures Navigating tight labor market with higher wage inflation, focusing on staffing levels across 40 states.

Outlook

New Credit Facility Active New $1.0B Revolving and $650.0M Term Loan Credit Facility closed February 2025, refinancing prior debt.
Growth Strategy Focus Strategy centers on five pathways: expansions, joint ventures, de novo facilities, acquisitions, and service continuum growth.
Share Repurchase Program $300.0M share repurchase program authorized; $250.0M remains available for purchases as of September 30, 2025.
Medicaid Financing Changes Monitoring OBBBA changes starting 2028 regarding provider tax arrangements and state directed payment caps.

Peer Comparison

Revenue (TTM)

Bausch Health Companies Inc.BHC
$8.26B
-12.7%
Ardent Health Partners, Inc.ARDT
$6.20B
+10.0%
Select Medical Holdings CorporationSEM
$5.37B
-23.0%

Gross Margin (Latest Quarter)

Bausch Health Companies Inc.BHC
173.2%
+101.0 pp
Acadia Healthcare Company, Inc.ACHC
96.7%
+72.8 pp
Inspire Medical Systems, Inc.INSP
84.0%
-0.7 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
HAE$3.44B19.919.4%50.1%
INSP$2.55B47.87.9%4.1%
BHC$2.37B6.6-38.2%78.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
+3.2%
Moderate Growth
4Q Net Income CAGR
+3.6%
Profitability Slowly Improving
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $851.57M+4.4%
    |
    EPS: $0.40-45.9%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 5, 2025|
    Revenue: $869.23M+9.2%
    |
    EPS: $0.33-61.6%
    Miss

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 12, 2025|
    Revenue: $770.51M+0.3%
    |
    EPS: $0.09-89.3%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $3.15B+7.7%
    |
    EPS: $2.79+1262.5%
    Beat

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $815.63M+8.7%
    |
    EPS: $0.74-131.0%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $796.04M+8.8%
    |
    EPS: $0.86+8.9%
    Meet

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $768.05M+9.1%
    |
    EPS: $0.84+15.1%
    Beat

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $2.93B+12.2%
    |
    EPS: $-0.24-107.9%
    Miss